Compare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x - -1.2 - View Chart
P/BV x 9.1 0.1 11,236.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
VENUS REMEDIES
Mar-18
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,589126 1,262.1%   
Low Rs1,23261 2,016.4%   
Sales per share (Unadj.) Rs417.5301.8 138.3%  
Earnings per share (Unadj.) Rs56.3-24.9 -226.4%  
Cash flow per share (Unadj.) Rs64.72.5 2,542.9%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9293.3 99.9%  
Shares outstanding (eoy) m119.5712.34 969.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,090.6%   
Avg P/E ratio x25.1-3.8 -666.5%  
P/CF ratio (eoy) x21.836.7 59.3%  
Price / Book Value ratio x4.80.3 1,510.3%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,154 14,617.3%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m9,171393 2,333.1%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m49,9153,724 1,340.3%  
Other income Rs m1,64523 7,311.6%   
Total revenues Rs m51,5613,747 1,376.2%   
Gross profit Rs m8,482395 2,148.5%  
Depreciation Rs m1,006338 297.3%   
Interest Rs m671354 189.3%   
Profit before tax Rs m8,451-275 -3,069.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60632 5,082.3%   
Profit after tax Rs m6,731-307 -2,193.3%  
Gross profit margin %17.010.6 160.3%  
Effective tax rate %19.0-11.5 -165.6%   
Net profit margin %13.5-8.2 -163.6%  
BALANCE SHEET DATA
Current assets Rs m27,0622,638 1,026.0%   
Current liabilities Rs m15,3242,305 664.9%   
Net working cap to sales %23.58.9 263.0%  
Current ratio x1.81.1 154.3%  
Inventory Days Days67135 49.1%  
Debtors Days Days4146 89.1%  
Net fixed assets Rs m12,6104,871 258.9%   
Share capital Rs m239123 193.8%   
"Free" reserves Rs m34,4903,496 986.6%   
Net worth Rs m35,0273,619 967.8%   
Long term debt Rs m1,2121,374 88.2%   
Total assets Rs m54,3877,509 724.3%  
Interest coverage x13.60.2 6,100.3%   
Debt to equity ratio x00.4 9.1%  
Sales to assets ratio x0.90.5 185.0%   
Return on assets %13.60.6 2,155.9%  
Return on equity %19.2-8.5 -226.6%  
Return on capital %24.91.6 1,571.2%  
Exports to sales %12.90-   
Imports to sales %3.113.9 22.2%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540517 298.2%   
Fx inflow Rs m6,5630-   
Fx outflow Rs m3,012517 583.1%   
Net fx Rs m3,552-517 -687.6%   
CASH FLOW
From Operations Rs m7,259514 1,411.1%  
From Investments Rs m1,864-123 -1,514.4%  
From Financial Activity Rs m-9,273-387 2,395.4%  
Net Cashflow Rs m-1504 -3,571.4%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  NATCO PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 173 Points Lower; IT and Realty Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure during closing hours today, tracking weakness in global markets owing to coronavirus outbreak.

Related Views on News

NILKAMAL Surges by 16%; BSE 500 Index Up 0.1% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

NILKAMAL share price has surged by 16% and its current market price is Rs 1,140. The BSE 500 is up by 0.1%. The top gainers in the BSE 500 Index are NILKAMAL (up 15.9%) and ALKEM LABORATORIES (up 13.9%). The top losers are INDRAPRASTHA GAS and INDIAN BANK (down 0.1%).

ABBOTT INDIA Surges by 6%; BSE HEALTHCARE Index Up 3.9% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

ABBOTT INDIA share price has surged by 6% and its current market price is Rs 18,245. The BSE HEALTHCARE is up by 3.9%. The top gainers in the BSE HEALTHCARE Index are ABBOTT INDIA (up 5.9%) and ALKEM LABORATORIES (up 13.7%). The top losers are SYNGENE INTERNATIONAL (down 0.8%) and GSK PHARMA (down 1.6%).

M&M FINANCIAL SERVICES Surges by 11%; BSE 500 Index Up 0.1% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

M&M FINANCIAL SERVICES share price has surged by 11% and its current market price is Rs 162. The BSE 500 is up by 0.1%. The top gainers in the BSE 500 Index are M&M FINANCIAL SERVICES (up 11.2%) and ALKEM LABORATORIES (up 14.1%). The top losers are HDFC and OIL INDIA (down 0.1%).

J.B.CHEMICALS Surges by 10%; BSE HEALTHCARE Index Up 4.6% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

J.B.CHEMICALS share price has surged by 10% and its current market price is Rs 546. The BSE HEALTHCARE is up by 4.6%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 10.0%) and ALKEM LABORATORIES (up 12.7%). The top losers are GSK PHARMA (down 0.1%) and ASTRAZENECA PHARMA (down 0.3%).

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Apr 8, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS